Akero Therapeutics, Inc. (NASDAQ:AKRO - Get Free Report) CEO Andrew Cheng sold 30,000 shares of the business's stock in a transaction on Thursday, April 10th. The shares were sold at an average price of $35.23, for a total value of $1,056,900.00. Following the completion of the transaction, the chief executive officer now owns 624,324 shares of the company's stock, valued at $21,994,934.52. This trade represents a 4.58 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink.
Andrew Cheng also recently made the following trade(s):
- On Wednesday, March 12th, Andrew Cheng sold 1,738 shares of Akero Therapeutics stock. The shares were sold at an average price of $44.88, for a total value of $78,001.44.
- On Monday, March 10th, Andrew Cheng sold 30,000 shares of Akero Therapeutics stock. The stock was sold at an average price of $41.77, for a total value of $1,253,100.00.
- On Monday, February 10th, Andrew Cheng sold 30,000 shares of Akero Therapeutics stock. The stock was sold at an average price of $52.73, for a total transaction of $1,581,900.00.
- On Monday, January 27th, Andrew Cheng sold 30,000 shares of Akero Therapeutics stock. The shares were sold at an average price of $54.90, for a total transaction of $1,647,000.00.
Akero Therapeutics Price Performance
Shares of NASDAQ AKRO opened at $35.67 on Friday. The business has a 50 day moving average price of $44.86 and a two-hundred day moving average price of $35.86. Akero Therapeutics, Inc. has a fifty-two week low of $17.86 and a fifty-two week high of $58.40. The firm has a market cap of $2.84 billion, a PE ratio of -9.51 and a beta of -0.18. The company has a quick ratio of 17.25, a current ratio of 17.25 and a debt-to-equity ratio of 0.05.
Akero Therapeutics (NASDAQ:AKRO - Get Free Report) last issued its quarterly earnings results on Friday, February 28th. The company reported ($0.99) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.98) by ($0.01). Sell-side analysts expect that Akero Therapeutics, Inc. will post -3.99 earnings per share for the current fiscal year.
Analyst Ratings Changes
A number of equities analysts have weighed in on AKRO shares. UBS Group lifted their price target on shares of Akero Therapeutics from $42.00 to $109.00 and gave the company a "buy" rating in a report on Friday, January 31st. Bank of America upgraded Akero Therapeutics from a "neutral" rating to a "buy" rating and raised their price objective for the stock from $35.00 to $63.00 in a report on Thursday, January 30th. Morgan Stanley reiterated an "overweight" rating on shares of Akero Therapeutics in a report on Sunday, March 2nd. HC Wainwright increased their price objective on shares of Akero Therapeutics from $72.00 to $75.00 and gave the stock a "buy" rating in a research report on Monday, March 3rd. Finally, Canaccord Genuity Group increased their price target on Akero Therapeutics from $56.00 to $73.00 and gave the company a "buy" rating in a report on Tuesday, January 28th. Nine analysts have rated the stock with a buy rating, According to MarketBeat.com, the stock has a consensus rating of "Buy" and an average target price of $76.29.
View Our Latest Stock Analysis on Akero Therapeutics
Institutional Investors Weigh In On Akero Therapeutics
Hedge funds and other institutional investors have recently modified their holdings of the stock. FMR LLC grew its stake in Akero Therapeutics by 732.1% in the third quarter. FMR LLC now owns 30,337 shares of the company's stock worth $870,000 after purchasing an additional 26,691 shares in the last quarter. XTX Topco Ltd acquired a new position in shares of Akero Therapeutics in the 3rd quarter worth approximately $308,000. Y Intercept Hong Kong Ltd increased its holdings in shares of Akero Therapeutics by 13.8% in the 3rd quarter. Y Intercept Hong Kong Ltd now owns 16,916 shares of the company's stock valued at $485,000 after acquiring an additional 2,049 shares during the last quarter. Barclays PLC raised its position in shares of Akero Therapeutics by 127.9% during the 3rd quarter. Barclays PLC now owns 127,668 shares of the company's stock valued at $3,662,000 after acquiring an additional 71,652 shares in the last quarter. Finally, Exome Asset Management LLC bought a new position in Akero Therapeutics during the third quarter worth $2,212,000.
About Akero Therapeutics
(
Get Free Report)
Akero Therapeutics, Inc, together with its subsidiary, engages in the development of treatments for patients with serious metabolic diseases in the United States. The company's lead product candidate is efruxifermin (EFX), which is in Phase 3 clinical trials that protects against cellular stress and regulates the metabolism of lipids, carbohydrates, and proteins throughout the body for the treatment of biopsy-confirmed metabolic dysfunction-associated steatohepatitis (MASH) patients.
Recommended Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. This story was reviewed by InsiderTrades.com's editorial team prior to publication. Please send any questions or comments about this story to contact@insidertrades.com.
